Outlook Therapeutics Inc (OTLK)

[pfelgueiras]

OTLK - They Started to Build the Sales Team

Executive Director, Provider Market Access
Job ID 2022-1788 Job Locations US-Remoted

Executive Director, Payer Market Access
Job ID 2022-1787 Job Locations US-Remote

Senior Vice President, Sales
Job ID 2022-1784 Job Locations US-Remote

(See more information about OTLK at r/OTLK_Investors)

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop and launch ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. Outlook Therapeutics expects to submit ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway during the first calendar quarter of 2022.

SOURCE:
https://careers-outlooktherapeutics.icims.com/jobs/search?ss=1